Pharmaceutical Processing

Although Pfizer (NYSE:PFE) has yet to receive emergency use authorization for its Paxlovid COVID-19 therapy, it plans to manufacture 80 million courses of the drug by the end of 2022. Pfizer had initially planned on making 50 million courses of Paxlovid (PF-07321332/ritonavir) in the same time frame. An interim analysis of the Phase 2/3 EPIC-HR…

Recently, General Electric (NYSE:GE), Zimmer Biomet (NYSE: ZBH) and Toshiba (TYO:6502) announced their plans to slim down by spinning out core businesses. Now, Johnson & Johnson (NYSE:JNJ) is following a similar approach by making its consumer health business a standalone company. J&J will retain its pharmaceutical and medical device segments. The company said in an…

The Oklahoma State Supreme Court has overturned a 2019 opioid judgment against Johnson & Johnson (NYSE:JNJ) amounting to $465 million. Five of the six Oklahoma Supreme Court’s justices dismissed the state’s case claiming that Johnson & Johnson breached its “public nuisance” laws in its marketing of prescription opioid drugs. “Oklahoma public nuisance law does not…

Moderna (NSDQ:MRNA) shares took a big hit today on third-quarter results that came up short of the consensus forecast. MRNA shares were down 17.1% at $286.80 per share in mid-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.2%. The Cambridge, Massachusetts-based company…

Catalent (NYSE:CTLT) shares dipped today despite first-quarter financial results that beat the consensus forecast. The Somerset, New Jersey-based company posted profits of $93 million, or 49¢ per share, on sales of $1.025 billion for the three months ended Sept. 30, 2021, for a 13.4% bottom-line gain on sales growth of 21.2%. Adjusted to exclude one-time…

AbbVie (NYSE:ABBV) shares ticked up before hours today on third-quarter results that beat the consensus forecast. The North Chicago, Illinois-based company posted profits of $3.2 billion, or $1.78 per share, on sales of $14.34 billion for the three months ended Sept. 30, 2021, for a 37.5% bottom-line gain on sales growth of 11.2%. Adjusted to…

Merck (NYSE:MRK) shares ticked up today on third-quarter results that beat the consensus forecast. The company also announced that it projects its oral COVID-19 antiviral molnupiravir to bring in between $5 billion and $7 billion in revenue next year. MRK shares were up 4.9% at $85.55 per share in early-morning trading today. MassDevice’s MedTech 100…

Eli Lilly (NYSE:LLY) shares slightly dipped today on third-quarter results that topped the consensus forecast. The Indianapolis-based company posted profits of $1.1 billion, or $1.22 per share, on sales of $6.8 billion for the three months ended Sept. 30, 2021, for a -8.1% bottom-line slide on sales growth of 18%. Adjusted to exclude one-time items,…

PerkinElmer (NYSE:PKI) announced today that it launched the Signals Research suite for pharmaceutical and industrial customers. Waltham, Massachusetts–based PerkinElmer’s full cloud-based Signals Research suite, deployed on Amazon Web Services (AWS) offers a secure informatics platform with integrated, end-to-end scientific data and workflow management for pharmaceutical and industrial customers. PerkinElmer designed the platform to help drive…

Rapid-acting insulin specialist MannKind Corp. (NSDQ:MNKD) has enrolled the first pediatric patient in its INHALE-1 study evaluating its Afrezza (Technosphere Insulin) with basal insulin versus multiple daily injections of insulin. The study will enroll participants aged four to 17 with type 1 or type 2 diabetes. Afrezza first won FDA approval in 2014, and MannKind…